Work

Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer

Year: 2025

Type: article

Abstract: Immune-

Source: Clinical and Translational Medicine

DOI: 10.1002/ctm2.70426

Authors: Eudald Felip, Edurne Garcia‐Vidal, Sara Cabrero‐de las Heras, Adrià Bernat‐Peguera, Beatriz Cirauqui, Milana Bergamino, Vanesa Quiroga, Iris Teruel, Angelica Ferrando‐Díez, Anna Pous, Assumpció Lopez‐Paradís, Laia Boronat, Marga Romeo, Ricard Mesía, Pedro Luis Fernandez, Bonaventura Clotet, Eva Riveira‐Muñoz, Anna Martínez‐Cardús, Ester Ballana, Mireia Margelí

Institutions: Universitat Autònoma de Barcelona, IrsiCaixa, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Institute for Bioengineering of Catalonia, Centro de Investigación Biomédica en Red, Centro de Investigación Biomédica en Red Enfermedades Infecciosas

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,470

Funders: Pfizer, Generalitat de Catalunya, Institute for Bioengineering of Catalonia, Instituto de Salud Carlos III

Awards: G2785854803, G5695560118, G6167528887, G7261578339, G7331421161

OpenAlex ID: W4413051265

FWCI: 1.181

Cites: 10

Cited by: 2

Related to: 10